BridgeBio Pharma, BridgeBio, Oral Infigratinib, Infigratinib, Achondroplasia, FDA, FDA Priority Review, NDA, PDUFA, February 4 2027, PROPEL 3, Phase 3, FGFR3, FGFR3 Inhibitor

PALO ALTO, Calif. — October 6, 2026 BridgeBio Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA)...